SPECIFIC ARTICLES AVAILABLE FOR DOWNLOAD AND BULK REPRINT

FOR ANY QUESTIONS PLEASE CONTACT THE PUBLISHER – ceo@medworksmedia.com

T.E.N Vol. 2 No. 2 – Jack Gorman’s Schizophrenia Endowment

IN THIS ISSUE:

  • 5 – Journal Mission/Objectives and Guide to Talking Points
  • 7 – Cover Essay: Jack Gorman
  • 15 – Letter from the Editor Myrna M. Weissman, PhD The Clinical Face of Economics: The Case of Schizophrenia
  • 16 – 30 Days Pharmacoeconomic news of the last 30 days Cost is a Major Healthcare Concern for Most People, Study: Low Income African American Women Need, More Information on Menopause, Once-A-Day Adderall for Attention-Deficit/Hyperactivity Disorder, Food and Drug Administration Approves, Levetiracetam as Antiepileptic, Eskalith Shortage Sparks Alternatives
  • 18 – Winners & Losers
  • 21 – Cost & Therapeutics Commentary by David Williamson, PhD The real-world costs of treating obesity
  • 22 – FDA Alert: Prescription Changes and Recalls
  • 24 – The TEN Clinical Trial Alert & Guide to Indigent Drug Services A state-by-state resource of open trials for major depression and a list of industry sponsored patient assistance medication programs
  • 30 – TEN Marketplace: CNS Agents and New Indications in Development
  • 33 – TEN Profile Understanding smoking behavior
  • 39 – The Role of the National Alliance for the Mentally Ill in Reversing the Economic Burden of Mental Illness – Laurie Flynn, Peter J. Weiden, MD
  • 42 – The Cost of Schizophrenia: Focus on Cognitive and Occupational Dysfunction – Philip D. Harvey, PhD, Susan R. McGurk, PhD
  • 51 – Human and Economic Costs of Schizophrenia: A Case Study of the Impact of Newer Antipsychotics – Seth A. Rafal, MD, MS, Ming T. Tsuang, MD, PhD
  • 56 – Pharmacologic Treatment of Schizophrenia – John M. Kane, MD
  • 65 – The Economic Implications of Schizophrenia: A Pharmacist’s Perspective – Julia E. Vertrees, PharmD, BCPP